Ventripoint Expands Subscription Access for FDA-Cleared AI Cardiac Imaging

Commercial initiative aims to make VMS+ easier for hospitals to evaluate and adopt TORONTO, Aug. 12, 2026 (GLOBE NEWSWIRE) — Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV: VPT; OTC: VPTDF), a leader in AI-assisted cardiac imaging, today announced the next phase of its commercial strategy for VMS+™ 4.0, its FDA-cleared platform that turns standard heart-ultrasound […]